Although there are proposed mechanisms for how 2HG acts as an ‘oncometabolite’, e.g. inhibition of chromatin modifying 2OG oxygenases by 2HG, further work is required to define and validate the proposed molecular links between IDH mutations and the processes of tumorigenesis leading to cancer and progression. Here, IDH2 is linked to cancer.